Related Research Articles
Virgil Craig Jordan,, is a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.
Richard G. Pestell is an Australian American oncologist and endocrinologist who is Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honours for distinguished service to medicine and medical education.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
Martine J. Piccart-Gebhart is a Belgian medical oncologist. She is a professor of oncology at the Université Libre de Bruxelles and scientific director at the Jules Bordet Institute in Brussels, Belgium. She is also a member of the Belgian Royal Academy of Medicine.
Dennis Joseph Slamon, is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the medical director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons’ laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of “broken immune tolerance” via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons’ clinical team took the biotechnology into the world’s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Henry Thompson Lynch was an American physician noted for his discovery of familial susceptibility to certain kinds of cancer and his research into genetic links to cancer.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine.
Joan S. Brugge is the Louise Foote Pfeiffer Professor of Cell Biology and the Director of the Ludwig Center at Harvard Medical School, where she also served as the Chair of the Department of Cell Biology from 2004 to 2014. Her research focuses on cancer biology, and she has been recognized for her explorations into the Rous sarcoma virus, extracellular matrix adhesion, and epithelial tumor progression in breast cancer.
Carlos L. Arteaga is the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.
Hope S. Rugo is professor of medicine and the director of the breast oncology clinical trials program at the University of California at San Francisco, and an investigator of SPORE in the Bay Area.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Reshma Jagsi is an American Radiation oncologist. She is the Lawrence W. Davis Professor and Chair in the Department of Radiation Oncology and Senior Faculty Fellow in the Center for Ethics at Emory University. Overall, she is the author of over 450 published articles in peer-reviewed medical journals and continues scholarly research in three primary areas of interest: breast cancer, bioethics, and gender equity, with the support of grants from the National Institutes of Health (NIH), the Doris Duke Charitable Foundation, and the Susan G. Komen Foundation, for which she serves as a Senior Scholar.
Helen Margaret Piwnica-Worms is an American cell-cycle researcher. Since 2013, she has served as vice provost of science at the MD Anderson Cancer Center and professor in MD Anderson's Department of Cancer Biology.
Mylin Ann Torres is an American breast cancer radiation oncologist. Torres is the Louisa and Rand Glenn Family Chair in Breast Cancer Research and director of the Glenn Family Breast Center.
Sendurai A. Mani is an Indian-American oncologist and a Molecular Bilogist. He is a fellow of the American Association for the Advancement of Sciences, and Dean's Chair for Translational Oncology at Brown University Warren Alpert Medical School. He is also the associate director for Translational Oncology at the Legorreta Cancer Center at Alpert Medical School, Brown University. Previously, he was a co-director of Metastasis Research Center and co-director, the Center for Stem Cell & Developmental Biology, and a professor of Translational Molecular Pathology at MD Anderson Cancer Center.
References
- 1 2 "Gordon B. Mills, M.D., Ph.D. | 2013 Susan G. Komen® Brinker Award for Scientific Distinction in Basic Science" (PDF). komen.org. Retrieved 2016-12-25.
- 1 2 "Gordon B. Mills, M.D., Ph.D. - Systems Biology - Faculty - MD Anderson Cancer Center". faculty.mdanderson.org. Retrieved 2016-12-25.
- ↑ "Stand Up To Cancer — Gordon B. Mills, M.D., Ph.D." standup2cancer.org. Retrieved 2016-12-25.
- ↑ "Gordon B. Mills | Breast Cancer Research Foundation | BCRF". Archived from the original on 2016-12-25. Retrieved 2016-12-25.
| Authority control databases: Academics |
|---|
